The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Flecainide modified release 200mg capsules (Tambocor XL®) have been accepted for use in treating a variety of cardiac arrhythmias including AV nodal reciprocating tachycardia, Wolff-Parkinson-White Syndrome and atrial fibrillation in patients with disabling symptoms. It is also noted that the once-daily product has a lower acquisition cost than a twice-daily product at equivalent doses.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Glitazones doubled fracture risk in women||One third obese by 2012 »|